Marseille

• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 5 Relapsed/refractory primary central nervous system lymphoma
• A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant … Pending
  2025-523481-24-00 5 Participants with Progressive Supranuclear Palsy Richardson Syndrome (
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Pending
  2025-523495-23-00 5 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• A Study to Learn about the Study Medicine called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Pending
  2025-523526-40-00 9 Advanced Solid Tumors
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Pending
  2025-523579-47-00 4 moderate to severe rheumatoid arthritis (RA)
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythema … Pending
  2025-523670-17-00 5 Systemic lupus erythematosus
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending
  2025-523895-22-00 4 Non-small cell lung cancer (NSCLC)
• TAR-0520 gel in Hand and Foot Syndrome Pending
  2025-524008-32-00 4 Capecitabine-induced hand and foot syndrome
• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Pending
  2025-524056-63-00 1 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) Pending
  2025-524181-26-00 4 relapsed/refractory multiple myeloma
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial Pending
  2025-524297-42-00 5 CLTI defined as Rutherford category 4 or 5
• Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy Pending
  2025-524317-88-00 4 Multiple System Atrophy
• OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Pending
  2025-524573-16-00 6 Crohn's disease
• Trial to study the safety and pharmacokinetics of ODM-212 combined with existing cancer treatments Pending
  2025-524620-22-00 9 Neoplasms benign malignant and unspecified (incl. cysts and polyps)
• Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum S … Pending
  2025-524978-42-00 4 Asymptomatic anal LGV infection
• Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer Recruiting
  2025-522888-15-00 3 2026-05-27 Small Cell Lung Cancer
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes

Showing 121–144 of 1,485 trials